Q2 2026 saw 4.5% sales growth and a 27% EBITDA margin, with record Americas sales and strong recurring reagent growth in APAC. EMEA stabilized post-inventory adjustment, and the Bone Marrow Aspirate Application launch and FDA progress support a positive outlook.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.